When Your Science Is Outsourced

Most writing about AI in biotech, some of mine included, pictures a company with its science in the building. Assay data on the servers, models trained on your own experiments, a discovery engine to make faster. If you run a clinical-stage company, that picture is not yours. Your bench is at the CROs. Your molecule is in trials you monitor rather than run. And your company, the part with employees and deadlines and risk, is something else entirely.

It is clinical operations, regulatory, medical writing, safety, and vendor oversight. That is where your people spend their days, and it is where AI actually touches your company. So the question is not how AI changes your lab. It is how AI changes a company that mostly writes, reviews, submits, and oversees, under rules written to protect patients. And that runs straight into the validated environment, which is exactly where most leaders assume AI cannot go.

Two lines decide where AI can help, and neither is the wall people imagine. The first is the data class you already know from your AI Use Policy: patient data and unfiled results are Tier 1 and live only in an approved, enterprise-secure environment. The second is subtler and matters more. It is whether AI is drafting something a qualified human owns and reviews, or becoming part of a system that creates or maintains a regulated record. The first is a question about your people and your programs. The second is a computer-system-validation and Part 11 question for your quality function. Most of the early value sits where neither line bites, and there is a great deal of it.

The validated gate is not there to keep AI out. It is there to protect patient safety and data integrity, and those do not get cheaper to ignore because intelligence got cheaper. So you do not relitigate the gate. You do the Permission work once, choose controls you can stand behind, and then ask the only interesting question left. Is the current shape of this gate still the best way to protect what it guards, or is it a manual step that survived because the old systems could not see each other. That question belongs to you and your quality function together, and it gets answered on purpose, not by waiting.

Here is Monday morning. Take one document your team writes by hand every week, a safety narrative, a monitoring summary, a submission section, and place it against the two lines. If it is a human-owned draft on data you already control, you can start this week. For everything past that line, bring your quality function in early and move it deliberately. The full map is the artifact above, and the destination it rests on is the AI-Native Biotech.

Cheers,
-Titus